Melatonin
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Melatonin |
| DrugBank ID | DB01065 |
| Brand Names (EU) | Melatonin Neurim |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.80% |
Approved Indication (EMA)
Melatonin Neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | insomnia (disease) | 99.80% | DL |
| 2 | sleep disorder, initiating and maintaining sleep | 96.11% | DL |
| 3 | migraine with brainstem aura | 87.90% | DL |
| 4 | obesity disorder | 85.77% | DL |
| 5 | restless legs syndrome | 85.65% | DL |
| 6 | migraine disorder | 85.52% | DL |
| 7 | hypervitaminosis | 84.39% | DL |
| 8 | obsolete hypertelorism (disease) | 83.11% | DL |
| 9 | monogenic obesity | 81.24% | DL |
| 10 | frontorhiny | 79.42% | DL |
| 11 | proximal 16p11.2 microdeletion syndrome | 78.45% | DL |
| 12 | acute encephalopathy with biphasic seizures and late reduced diffusion | 78.33% | DL |
| 13 | fibrosis of extraocular muscles, congenital, with synergistic divergence | 69.86% | DL |
| 14 | hypercarotenemia and vitamin A deficiency, autosomal recessive | 69.10% | DL |
| 15 | hyperparathyroidism, primary, caused by water clear cell hyperplasia | 67.85% | DL |
| 16 | retinal aplasia | 66.11% | DL |
| 17 | melanoma, malignant familial intraocular | 64.98% | DL |
| 18 | atrophoderma vermiculata | 64.46% | DL |
| 19 | triphalangeal thumb, Nonopposable | 64.13% | DL |
| 20 | sella turcica, bridged | 64.13% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.